-transparent.png){kind=logo}
Pala, 5G /M2 i.v. every 3 weeks was given to 32 evaluable patients with ovarian carcinoma (31 previously treated). No complete or partial responses were noted. Ten patients had stable disease for a median progression-free interval of 4.7+ months, while the remainder had progression of disease from the start of therapy. The major toxicity was dermatologic, and five patients had severe skin rash with desquamation or ulceration. There was no substantial hematologic or gastrointestinal toxicity. PALA displays no useful activity in previously-treated patients with ovarian cancer.
Related Publications
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
December 1984,
American journal of clinical oncology,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
December 1984,
American journal of clinical oncology,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
August 1986,
American journal of clinical oncology,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
August 1987,
American journal of clinical oncology,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
August 1985,
American journal of clinical oncology,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
January 1986,
Investigational new drugs,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
November 1990,
Investigational new drugs,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
February 1990,
American journal of clinical oncology,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
May 1990,
Investigational new drugs,
H B Muss, and
M Slavik, and
B Bundy, and
F B Stehman, and
W T Creasman
August 1990,
American journal of clinical oncology,
